Shares of Revance Therapeutics Inc. (RVNC), which were trading around $37 at its peak in 2014, have significantly declined in value and trade around $7.
The company's flagship product is Daxxify, a neuromodulator, which was approved by the FDA for frown line treatment in September 2022, and for the treatment of cervical dystonia last August.
According to the company, Daxxify has had the most successful neuromodulator launch compared to the last three neuromodulators to enter the market, say Ipsen's Dysport, Merz Pharma's Xeomin, Evolus' Jeuveau, in their respective launch periods.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.